Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
PTC Therapeutics (PTCT)
NASDAQ:PTCT
PTC Therapeutics (PTCT) Stock Price & Analysis
302 Followers
PTCT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$17.53 - $59.84
Previous Close$33.1
Volume646.62K
Average Volume (3M)864.50K
Market Cap
$2.54B
Enterprise Value$2.95B
Total Cash (Recent Filing)$294.81M
Total Debt (Recent Filing)$704.35M
Price to Earnings (P/E)-4.3
Beta1.00
Next Earnings
Aug 01, 2024EPS Estimate
-$1.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.68
Shares Outstanding76,696,785
10 Day Avg. Volume620,531
30 Day Avg. Volume864,499
Standard Deviation0.14
R-Squared0.06
Alpha0.00114
Financial Highlights & Ratios
Price to Book (P/B)-2.04
Price to Sales (P/S)15.16
Price to Cash Flow (P/CF)-6.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.88
Enterprise Value/Gross Profit4.22
Enterprise Value/Ebitda-8.35
Forecast
1Y Price Target
$29.30Price Target Upside-11.47% Downside
Rating ConsensusHold
Number of Analyst Covering11
PTC Therapeutics News
PremiumCompany Announcements
PTC Therapeutics Q1 Financial Results Conference Call
Bulls Say, Bears Say
Bulls Say
Drug Approval And Revenue ProjectionsEvrysdi has been approved in most major markets, which is expected to boost global sales and generate projected revenues of $3 billion for PTC Therapeutics.
Financial HealthPTC Therapeutics has a robust financial position with $884.8 million in cash, cash equivalents, and marketable securities, signaling strong liquidity and potential for future investments.
Pipeline DevelopmentThe planned submission of New Drug Applications for multiple treatments shows significant progress in PTC Therapeutics' pipeline, potentially leading to new growth avenues.
Bears Say
Financial GuidanceDespite a strong start to the year, the unchanged full-year guidance for 2024 raises concerns over the sustainability of the current sales trend.
Market CompetitionEmflaza's market position is at risk due to the introduction of generic competitors from companies like India’s Aurobindo, threatening its sales and profitability.
Regulatory ChallengesThe European Commission's delay in deciding on Translarna's future, combined with skepticism about a positive outcome, poses a significant threat to its market availability.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PTCT FAQ
What was PTC Therapeutics’s price range in the past 12 months?
PTC Therapeutics lowest stock price was $17.53 and its highest was $59.84 in the past 12 months.
What is PTC Therapeutics’s market cap?
Currently, no data Available
When is PTC Therapeutics’s upcoming earnings report date?
PTC Therapeutics’s upcoming earnings report date is Aug 01, 2024 which is in 75 days.
How were PTC Therapeutics’s earnings last quarter?
PTC Therapeutics released its earnings results on Apr 25, 2024. The company reported -$1.2 earnings per share for the quarter, beating the consensus estimate of -$1.275 by $0.075.
Is PTC Therapeutics overvalued?
According to Wall Street analysts PTC Therapeutics’s price is currently Overvalued.
Does PTC Therapeutics pay dividends?
PTC Therapeutics does not currently pay dividends.
What is PTC Therapeutics’s EPS estimate?
PTC Therapeutics’s EPS estimate is -$1.26.
How many shares outstanding does PTC Therapeutics have?
PTC Therapeutics has 76,696,785 shares outstanding.
What happened to PTC Therapeutics’s price movement after its last earnings report?
PTC Therapeutics reported an EPS of -$1.2 in its last earnings report, beating expectations of -$1.275. Following the earnings report the stock price went up 12.083%.
Which hedge fund is a major shareholder of PTC Therapeutics?
Among the largest hedge funds holding PTC Therapeutics’s share is Blackstone Inc.. It holds PTC Therapeutics’s shares valued at 32M.
---
PTC Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$29.30 (-11.47% Downside)
$29.30 (-11.47% Downside)
Blogger Sentiment
Bullish
PTCT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 331.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $156.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-43.22%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.24%
Trailing 12-Months
Company Description
PTC Therapeutics
PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
---
PTCT Earnings Call
Q1 2024
0:00 / 0:00
---
PTCT Stock 12 Month Forecast
Average Price Target
$29.30
▼(-11.47% Downside)
Technical Analysis
Sarepta Therapeutics
―
Ultragenyx Pharmaceutical
―
Crispr Therapeutics AG
―
Bluebird Bio
―
Best Analysts Covering PTCT
1 Year
1 Year Success Rate
10/16 ratings generated profit
1 Year Average Return
+6.71%
reiterated a buy rating 2 months ago
Copying Eric Joseph's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +6.71% per trade.
---